BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 22684726)

  • 21. Evaluation of several screening approaches for detection of cervical lesions in rural Shandong, China.
    Zong LJ; Zhang YZ; Yang XS; Jiang J; Cui BX; Qiao YB; Li L; Jiang K; Zhang WJ; Kong BH; Shen K
    Asian Pac J Cancer Prev; 2015; 16(5):1907-12. PubMed ID: 25773843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening for cervical cancer in high-risk populations: DNA pap test or Hybrid Capture II test alone?
    Miranda Pereira SM; Castelo A; Makabe S; Utagawa ML; Di Loreto C; Sakamoto Maeda MY; Marques JA; Santoro CL; Filho AL; Das Dores GB
    Int J Gynecol Pathol; 2006 Jan; 25(1):38-41. PubMed ID: 16306782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human papillomavirus and Papanicolaou tests to screen for cervical cancer.
    Naucler P; Ryd W; Törnberg S; Strand A; Wadell G; Elfgren K; Rådberg T; Strander B; Johansson B; Forslund O; Hansson BG; Rylander E; Dillner J
    N Engl J Med; 2007 Oct; 357(16):1589-97. PubMed ID: 17942872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HPV testing in first-void urine provides sensitivity for CIN2+ detection comparable with a smear taken by a clinician or a brush-based self-sample: cross-sectional data from a triage population.
    Leeman A; Del Pino M; Molijn A; Rodriguez A; Torné A; de Koning M; Ordi J; van Kemenade F; Jenkins D; Quint W
    BJOG; 2017 Aug; 124(9):1356-1363. PubMed ID: 28391609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lower cost strategies for triage of human papillomavirus DNA-positive women.
    Qiao YL; Jeronimo J; Zhao FH; Schweizer J; Chen W; Valdez M; Lu P; Zhang X; Kang LN; Bansil P; Paul P; Mahoney C; Berard-Bergery M; Bai P; Peck R; Li J; Chen F; Stoler MH; Castle PE
    Int J Cancer; 2014 Jun; 134(12):2891-901. PubMed ID: 24248915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immediate histopathologic follow-up of cervista and aptima high-risk HPV assays in women with LSIL cytology.
    Zhang H; Varma KR; Han M; Matsko J; Zhao C
    Cancer Cytopathol; 2018 Aug; 126(8):525-532. PubMed ID: 29797678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the AMPLICOR human papillomavirus test and the hybrid capture 2 assay for detection of high-risk human papillomavirus in women with abnormal PAP smear.
    De Francesco MA; Gargiulo F; Schreiber C; Ciravolo G; Salinaro F; Manca N
    J Virol Methods; 2008 Jan; 147(1):10-7. PubMed ID: 17854914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.
    Naucler P; Ryd W; Törnberg S; Strand A; Wadell G; Elfgren K; Rådberg T; Strander B; Forslund O; Hansson BG; Hagmar B; Johansson B; Rylander E; Dillner J
    J Natl Cancer Inst; 2009 Jan; 101(2):88-99. PubMed ID: 19141778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design and methods of the evaluation of an HPV-based cervical cancer screening strategy in Mexico: The Morelos HPV Study.
    Flores Y; Shah K; Lazcano E; Hernández M; Bishai D; Ferris DG; Lörincz A; Hernández P; Salmerón J;
    Salud Publica Mex; 2002; 44(4):335-44. PubMed ID: 12216521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-Risk HPV Testing in Primary Screening for Cervical Cancer in the Public Health System, São Paulo, Brazil.
    Levi JE; Martins TR; Longatto-Filho A; Cohen DD; Cury L; Fuza LM; Villa LL; Eluf-Neto J
    Cancer Prev Res (Phila); 2019 Aug; 12(8):539-546. PubMed ID: 31189569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparing PAP smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS study.
    Syrjänen K; Naud P; Derchain S; Roteli-Martins C; Longatto-Filho A; Tatti S; Branca M; Erzen M; Hammes LS; Matos J; Gontijo R; Sarian L; Braganca J; Arlindo FC; Maeda MY; Lörincz A; Dores GB; Costa S; Syrjänen S
    Anticancer Res; 2005; 25(5):3469-80. PubMed ID: 16101165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method.
    Zhao FH; Lewkowitz AK; Chen F; Lin MJ; Hu SY; Zhang X; Pan QJ; Ma JF; Niyazi M; Li CQ; Li SM; Smith JS; Belinson JL; Qiao YL; Castle PE
    J Natl Cancer Inst; 2012 Feb; 104(3):178-88. PubMed ID: 22271765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Human papillomavirus testing in cervical cancer screening at a public health service of Santiago, Chile].
    Terrazas S; Ibáñez C; Lagos M; Poggi H; Brañes J; Barriga MI; Cartagena J; Núñez F; González F; Cook P; Van De Wyngard V; Ferreccio C
    Rev Med Chil; 2015 Jan; 143(1):56-62. PubMed ID: 25860269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis.
    Arbyn M; Verdoodt F; Snijders PJ; Verhoef VM; Suonio E; Dillner L; Minozzi S; Bellisario C; Banzi R; Zhao FH; Hillemanns P; Anttila A
    Lancet Oncol; 2014 Feb; 15(2):172-83. PubMed ID: 24433684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The HPV test has similar sensitivity but more overdiagnosis than the Pap test--a randomised health services study on cervical cancer screening in Finland.
    Malila N; Leinonen M; Kotaniemi-Talonen L; Laurila P; Tarkkanen J; Hakama M
    Int J Cancer; 2013 May; 132(9):2141-7. PubMed ID: 22987601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Performance of human papillomavirus typing test in cervical precancer lesions and cervical cancer screening].
    Zhang SK; Luo XP; Li ZF; Su Z; Xia JC; Hu GY; Zhu YJ; Xie LX; Feng XX; Sun XB; Chen W; Qiao YL
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):252-256. PubMed ID: 32252206
    [No Abstract]   [Full Text] [Related]  

  • 37. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
    Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
    Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear.
    Molden T; Nygård JF; Kraus I; Karlsen F; Nygård M; Skare GB; Skomedal H; Thoresen SO; Hagmar B
    Int J Cancer; 2005 May; 114(6):973-6. PubMed ID: 15645423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HPV detection in a self-collected vaginal swab combined with VIA for cervical cancer screening with correlation to histologically confirmed CIN.
    Kamal EM; El Sayed GA; El Behery MM; El Shennawy GA
    Arch Gynecol Obstet; 2014 Dec; 290(6):1207-13. PubMed ID: 25009070
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-risk HPV DNA detection by Hybrid Capture II. An adjunctive test for mildly abnormal cytologic smears in women > or = 50 years of age.
    Lin CT; Tseng CJ; Lai CH; Hsueh S; Huang HJ; Law KS
    J Reprod Med; 2000 Apr; 45(4):345-50. PubMed ID: 10804494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.